Genetics of Alzheimer disease in the pre- and post-GWAS era
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research. The identification of deterministic mutations in the APP, PSEN1, and PSEN2 genes responsible for early-onset autosomal dominant familial forms of AD led to a better understanding of the pathophysiology of this disease. In the past decade, the plethora of candidate genes and regions emerging from genetic linkage and smaller-scale association studies yielded intriguing 'hits' that have often proven difficult to replicate consistently. In the last two years, 11 published genome-wide association studies (GWASs) in AD confirmed the universally accepted role of APOE as a genetic risk factor for late-onset AD as well as generating additional candidate genes that require confirmation. It is unclear whether GWASs, though a promising novel approach in the genetics of complex diseases, can help explain most of the underlying genetic risk for AD. This review provides a brief summary of the genetic studies in AD preceding the GWAS era, with the main focus on the findings from recent GWASs. Potential approaches that could provide further insight into the genetics of AD in the post-GWAS era are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Th e identifi cation of homology in the Aβ peptide isolated from brains of patients with AD and trisomy 21 (Down syndrome) and localization of the amyloid precursor protein (APP) to chromosome 21 [9,10], where linkage to disease risk was mapped in early-onset familial AD (EOFAD) families [11,12], led to the discovery…”
BackgroundA second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 2×
“Accordingly, there are currently 32 mutations in APP, 177 in PSEN1, and 14 in PSEN2, identifi ed in 86, 392, and 23 families, respectively.”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
The International SNP Map Working Group, Laboratories:, C. S. H., Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., National Center for Biotechnology Information:, Marth, G., Sherry, S., et al. (2001) · Nature · doi:10.1038/35057149 · Cited by 2,977
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 2×
“Accordingly, there are currently 32 mutations in APP, 177 in PSEN1, and 14 in PSEN2, identifi ed in 86, 392, and 23 families, respectively.”
BackgroundLohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S., & Hirschhorn, J. N. (2003) · Nature Genetics · doi:10.1038/ng1071 · Cited by 1,900 · cited 1×
“Potential problems in candidate gene association studies of AD and proposed solutions are discussed elsewhere [29,45,46] and will be briefl y mentioned here.”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 6×
“Some of these regions were detected in multiple independent studies, strongly suggesting the presence of non-APOE genetic factors underlying the risk of AD. Loci on chromosomes 6, 9, 10, and 12 [ 29 ,35] yielded multiple, independent, strong signals that led to subsequent fi nemapping eff orts, which have proven diffi…”
BackgroundMethodResultInfluentialRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 3×
“Th ere is evidence from familial aggregation, transmission patterns, and twin studies that AD has a substantial genetic component that has an estimated heritability of 58% to 79% [4], and the lifetime risk of AD in fi rst-degree relatives of patients may be twice that of the general population [5].”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“Despite the rarity of APP and PSEN mutations, their functional evaluation in transfected cells [ 19 ,20], transgenic animals [21,22], and human plasma [23] identifi ed elevations in Aβ levels, increased Aβ42/ Aβ40 ratio, or fi brillogenesis, which constituted the cornerstone of the amyloid cascade hypothesis [24].”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“In vitro and in vivo studies also suggest a role for APOE in isoform-specifi c synaptogenesis and cognition, neurotoxicity, tau hyperphosphorylation, neuroinfl ammation, and brain metabolism, although these non-Aβ-related mechanisms require further investigation [34].”
BackgroundAmyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611 · cited 1×
“Th e identifi cation of homology in the Aβ peptide isolated from brains of patients with AD and trisomy 21 (Down syndrome) and localization of the amyloid precursor protein (APP) to chromosome 21 [9,10], where linkage to disease risk was mapped in early-onset familial AD (EOFAD) families [11,12], led to the discovery…”
BackgroundBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · cited 1×
“Th e use of APOE as a diagnostic [36] or predictive factor in clinical practice is not warranted.”
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157 · cited 1×
“APOE is a component of senile plaques [ 30 ], binds Aβ [31], can infl uence neuritic plaque formation in transgenic mouse models of AD in an isoform-specifi c fashion [32], and is thought to contribute to both Aβ clearance and deposition in the brain [33].”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“APOE is a component of senile plaques [30], binds Aβ [31], can infl uence neuritic plaque formation in transgenic mouse models of AD in an isoform-specifi c fashion [32], and is thought to contribute to both Aβ clearance and deposition in the brain [33].”
BackgroundMultimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 1×
“Early-onset familial Alzheimer disease Alzheimer disease (AD), the most common dementia, currently aff ects an estimated 35 million patients worldwide [1] and is characterized by extracellular accumu lation of the amyloid β (Aβ) peptide in senile plaques and intracellular accumulation of the abnormally hyperphosphoryl…”
BackgroundCoon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 1×
“Th ere exist alternative hypo theses suggesting tau [ 25 ] or dominant negative loss”
BackgroundBertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 3×
“Bertram et al. [ 55 ], November 2008 US Family-based 1 discovery and 3 replication series Aff ymetrix 500K 404,604 941 404 1,767 838 Signifi cance after weighted-Bonferroni correction”
BackgroundMethodCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 2×
“Th e third LOAD GWAS [53] analyzed more than 400,000 SNPs from the Aff ymetrix 500K platform in 753 AD patients and 736 controls from the discovery series and followed up the 120 top SNPs in the 418 AD patients and 249 controls from the replication series.”
BackgroundShen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 1×
“of presenilin function [ 26 ] as additional pathophysiologic mechanisms underlying AD.”
BackgroundSlooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399 · cited 1×
“PAR esti mates may have an upward bias in family-based studies and younger populations given that APOE has a stronger eff ect in younger ages (from younger than age 70 to eighties) and longitudinal studies may provide more accurate estimates of PAR of APOE where estimates of 20% were obtained [35,37,38].”
BackgroundAPOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Lautenschlager, N. T., Cupples, L. A., Rao, V. S., Auerbach, S. A., Becker, R., Burke, J., Chui, H., Duara, R., Foley, E. J., Glatt, S. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.641 · Cited by 298
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296 · cited 11×
“Th e authors also identifi ed nominal signifi cance for SNPs in PICALM (P = 1.0 × 10−2 to 1.0 × 10−3) and PCDH11X (0.01 P 0.05) in their series, thereby providing additional evidence for these genes identifi ed in other LOAD GWASs [59,60].”
BackgroundResultInfluentialSelf-citationThe Number of Trait Loci in Late-Onset Alzheimer Disease
Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., & Wijsman, E. M. (2000) · The American Journal of Human Genetics · doi:10.1086/302710 · Cited by 295
Grupe, A., Abraham, R., Li, Y., Rowland, C., Hollingworth, P., Morgan, A., Jehu, L., Segurado, R., Stone, D., Schadt, E., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm031 · Cited by 289
PREDISPOSING LOCUS FOR ALZHEIMER'S DISEASE ON CHROMOSOME 21
Goate, A., Owen, M., James, L., Mullan, M., Rossor, M., Haynes, A., Farrall, M., Lai, L. C., Roques, P., Williamson, R., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91725-x · Cited by 270 · cited 1×
“Th e identifi cation of homology in the Aβ peptide isolated from brains of patients with AD and trisomy 21 (Down syndrome) and localization of the amyloid precursor protein (APP) to chromosome 21 [9,10], where linkage to disease risk was mapped in early-onset familial AD (EOFAD) families [11,12], led to the discovery…”
BackgroundGenome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer Disease
Beecham, G. W., Martin, E. R., Li, Y.-J., Slifer, M. A., Gilbert, J. R., Haines, J. L., & Pericak-Vance, M. A. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.008 · Cited by 260 · cited 1×
“Alzheimer disease GWASs Th e study designs and results of the 11 LOAD GWASs are depicted in detail in Tables 1 and 2, respectively [50-61].”
BackgroundA genome-wide association study for late-onset Alzheimer's disease using DNA pooling
Abraham, R., Moskvina, V., Sims, R., Hollingworth, P., Morgan, A., Georgieva, L., Dowzell, K., Cichon, S., Hillmer, A. M., O'Donovan, M. C., et al. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-44 · Cited by 195 · cited 2×
“Alzheimer disease GWASs Th e study designs and results of the 11 LOAD GWASs are depicted in detail in Tables 1 and 2, respectively [50-61].”
BackgroundMethodPeripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175
Evidence for CALM in Directing VAMP2 Trafficking
Harel, A., Wu, F., Mattson, M. P., Morris, C. M., & Yao, P. J. (2008) · Traffic · doi:10.1111/j.1600-0854.2007.00694.x · Cited by 144 · cited 1×
“Th ere is also evidence that PICALM infl uences endocytosis of the synaptic vesicle protein VAMP2 from the plasma mem brane [ 70 ], suggesting a role in synaptic function.”
BackgroundExamination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128 · cited 1×
“Alzheimer disease GWASs Th e study designs and results of the 11 LOAD GWASs are depicted in detail in Tables 1 and 2, respectively [50-61].”
Background
Cited by
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Cruchaga, C., Chakraverty, S., Mayo, K., Vallania, F. L. M., Mitra, R. D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., Foroud, T. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031039 · Cited by 320
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312
Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70323-9 · Cited by 263
Genetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Metadata
- Authors
- Ertekin-Taner, N.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2010
- Volume
- 2
- Issue
- 1
- Pages
- 3
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2142814611
- Cited by
- 106
- References
- 39
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.